In recent years, targeted protein degradation (TPD) has emerged as a groundbreaking strategy in drug discovery and molecular biology research. Unlike traditional inhibition-based approaches, TPD technologies leverage the body's natural protein degradation machinery, offering unique advantages in targeting previously "undruggable" proteins. Central to this approach are E3 ubiquitin ligases,...